| 摘要 |
Oligonucleotides for use in the treatment of cancer wherein said treatment is an immunological therapy and comprises the administration of an antibody to the patient, and wherein said antibody is administered before the administration of an antibody. The oligonucleotide is administered topically to a mucous membrane or subcutaneously in a dose effective to up-regulate the expression of at least one of the cell surface markers CD20, CD23, CD25, CD40, CD54, CD69, CD80, and CD86, to activate NK-cells, and/or induce apoptosis. |
